Sentences with phrase «at earnings levels»

In Section 2, it was noted that the earnings replacement capacity of the Canadian RIS is quite complete based on the first two pillars alone at earnings levels up to one - half of average wages and salaries, but declines thereafter.

If you look at the data I presented in my previous post, I estimate roughly how many authors should be expected at each earnings level.

Not exact matches

SmartAsset looked at the median earnings for full - time working women, as well as the number of women with high - level degrees and those who own businesses.

The S&P 500's forward price - to - earnings, or P / E, ratio is a shade under 17 times right now, putting it at its lowest level since 2016 and just 11 % above its long - term average, according to BAML.

Can valuations stay at the level that they are or is the stock performance going to be capped at how much earnings growth is?

That was until 2006's «Halloween Surprise,» when then finance minister Jim Flaherty introduced a law to make those kinds of earnings fully taxable at the corporate level, beginning in 2011.

«They're changing the way we watch TV and the way we stream video, but at 70 times earnings for a company that doesn't generate any cash flow, it's hard for me to invest at these levels.»

With the dollar now at the lowest level it's been in a decade, receipts in foreign currency are starting to translate into higher earnings, faster sales growth or both.

Traditional C - corporation status provides the protection of limited liability for shareholders, but at a cost of double taxation of earnings — at both the corporate and shareholder levels.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

«We believe the bias for stock prices in general remains to the upside, underpinned by a growing economy, low interest rates and increasingly, cheaper oil... With operating margins at elevated levels, top line growth is poised to more quickly bleed through to the bottom line, thus supporting earnings.»

The election takes place amidst an improving global economy with global earnings revision ratios at 5.5 - year highs, global PMI's at their highest levels since early - 2014, Asian exports at 12 - month highs and US wage growth at 7 - year highs.

However, at nearly 63 times current earnings - a whopping p / e ratio, to be sure - even if the firm were to grow its profit to the level of Berkshire - $ 8.5 billion - it would still lack the liquid assets and marketable securities the house that Warren Buffett built has, and it would not have a diversified income stream, making it far more vulnerable to changes in the competitive landscape; a major concern when you contemplate that Google operates in an industry where dramatic shifts consumer behavior can happen overnight.

At the same time, an implicit assumption of Canadian pension policy has been that beyond a certain level of earnings, people should look after themselves.

In Table 1, benefits provided by Pillars 1 and 2 are expressed as replacement rates at three levels of earnings: 0.5 times average wages; 1.0 times average wages; and 1.5 times average wages.

Elsewhere, the MSCI Emerging Markets Index, which has been particularly hard hit, is trading at less than 12x earnings and barely 1.25 x book, a level last seen during the lows in early 2009.

EWZ is trading at about 9 times trailing earnings, one of the lowest for emerging markets and near the P / E level of March 2009, just before it took off.

Compared to where it was a year ago today, the stock is now trading at a higher level, reflecting both the market's overall trend during that period and the fact that the company's earnings growth has been robust.

Profit margins and earnings growth have remained at record levels, despite weak global growth and a number of other macro threats.

The price to earnings ratio (P / E) tells an investor how many years it will take to return his investment were the company earnings maintained at a constant level, and were all those earnings to be paid to the shareholder.

One possible explanation is that earnings are at an unusually high level and likely to revert to normal levels that would be a reason why earnings - price ratios are low.

On the other hand, it is important to note that the spread between earnings price ratios and real interest rates are at near record levels, and that is a crude measure of the equity risk premium.

This observation is based on our analysis of JETS at the stock level, where we analyze earnings quality, true profitability and the market - implied cash flow expectations embedded in stock prices.

The WisdomTree India Earnings Fund ($ EPI) has pulled back to new support of the prior breakout level at the $ 20 level, and is holding up so far.

Although a number of factors led to this decision, a few worth noting are a modest level of debt (22 % of the capital structure, as shown in the Capital Structure box), ample cash (nearly $ 15 billion at yearend 2011, as noted in the Current Position box, which is directly below the Capital Structure box), and a lengthy history of solid earnings (which can be seen in the Statistical Array).

An investor would be well served to ignore the buy, sell or hold recommendation S&P attaches to each of the reports, instead looking at the growth in earnings, debt levels and the return on equity rates for past several years.

Companies that can maintain at least some level of earnings are, on the whole, more stable.

Only a combination of ignorance and alchemy would reward this higher level of earnings with a high P / E, when the source of the earnings was the acquisition of companies valued at low P / Es.

If we examine median price / earnings ratios of different groups in the S&P 500 at the 2000 market peak and at current levels, we observe the following pattern:

The Wells Fargo Investment Institute recently suggested that earnings growth may have peaked in the first quarter, while Morgan Stanley calculated that expectations for stock returns were at their lowest level since before the financial crisis.

Add the fact that much of the earnings - per - share growth is created by making acquisitions of slower growing, lower P / E companies, and one might think that the new, larger level of earnings should be valued at a smaller multiple than the prior earnings were.

On the other end of the spectrum, if investors feel that future earnings will be underwhelming, its P / E ratio may languish at a relatively low level.

Stock prices are up and valuations are at extreme levels despite faltering earnings, Fed rate hikes and a slowing economy.

Adjusted net income came in at $ 4.78 billion, up about 10 % from year - ago levels, and that worked out to adjusted earnings of $ 1.74 per share, topping the consensus forecast for $ 1.72 per share among those following the stock.

Higgins adds that valuations were much more frothy: «Back [in the 90s], the price / 12m trailing operating earnings ratio of the S&P 500 climbed to around 30 at its peak, which was roughly double its level in 1994.

Currently, the S&P 500 trades at about 10.3 times the level of earnings observed last year.

While the current price / peak - earnings multiple is already at an elevated level above 18, what I'll call the «P / E equivalent» multiples on other fundamentals are: 21 on the basis of book values, nearly 23 on the basis of enterprise value / EBITDA (which factors in the increasing share of debt on corporate balance sheets), over 25 on the basis of revenues, and 29 on the basis of dividends (largely because dividend payout ratios remain relatively low even on the basis of normalized earnings).

Although at 22 time trailing twelve month earnings the market may seem expensive, selling your stocks on some magic valuation level and fear will actually make you wrong.

If this earnings growth result stays at this level, it will be the second highest earnings season since 2011 as in that year we saw 11.6 % earnings growth.

At the company level, Bank of America and Morgan Stanley are the key drivers of growth in the sector, due in part to comparisons to weak earnings in the third quarter of 2012.

«Earnings and revenues are going to take the next level of the market to new highs,» says Rosenberg, who adds that the market isn't overvalued at current levels.

At current levels, Japanese equities are both absolutely and relatively cheap; the equity risk premium is about 7.8 % and the forward price / earnings ratio is less than 13.

The cyclically adjusted price - to - earnings (P / E) ratio for U.S. stocks was at its highest level since March 2002 as of end - July according to Thomson Reuters data, a level last associated with a major market correction.

These experience earnings growth of at significant levels, 70 percent, 40 percent.

The Swiss government argued that to allow the franc to continue at such an elevated level would hurt Swiss exporters and create a drag on their earnings.

The price - earnings (P / E) ratio for the S&P has stabilised at around 30, though it remains at a level well above its long - run average of 14 (Graph 14).

A prudent investor will look at companies that have earnings with a high level of predictability that has been proven that they can can make money.

The Shiller Cyclically Adjusted Price to Earnings Ratio P / E10 is at high level of 33.5 (and P / E5 of 28.0), and a market correction is possible.

Firms of growth stocks all trade at high valuation levels, meaning they usually have high price - to - earnings (P / E) ratios.

The S&P 500 trades today at just 15.6 times average estimated earnings — well below the average P / E of 18.6 times earnings during periods when inflation was at similarly muted levels in the past 57 years...